Literature DB >> 17108132

The internalization and degradation of human copper transporter 1 following cisplatin exposure.

Alison K Holzer1, Stephen B Howell.   

Abstract

The human copper transporter 1 (hCTR1), the major transporter responsible for copper influx, mediates one component of the cellular accumulation of cisplatin (DDP). Both copper and DDP cause rapid down-regulation of hCTR1 expression in human ovarian carcinoma cells. In this study, we investigated the mechanism of this effect using digital deconvolution microscopy and Western blot analysis of cells stained with antibodies directed at both ends of the protein. Treatment of 2008 cells with DDP in combination with inhibitors of various endosomal pathways (amiloride, cytochalasin D, nystatin, and methyl-beta-cyclodextrin) showed that hCTR1 degradation was blocked by amiloride and cytochalasin D, indicating that hCTR1 was internalized primarily by macropinocytosis. Expression of transdominant-negative forms of dynamin I and Rac showed that loss of hCTR1 was not dependent on pathways regulated by either of these proteins. DDP-induced loss of hCTR1 was blocked by the proteasome inhibitors lactacystin, proteasome inhibitor 1, and MG132. This study confirms that DDP triggers the rapid loss of hCTR1 from ovarian carcinoma cells at clinically relevant concentrations. The results indicate that DDP-induced loss of hCTR1 involves internalization from the plasma membrane by macropinocytosis followed by proteasomal degradation. Because hCTR1 is a major determinant of early DDP uptake, prevention of its degradation offers a potential approach to enhancing tumor sensitivity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17108132     DOI: 10.1158/0008-5472.CAN-06-1710

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  52 in total

1.  The role of the N-terminus of mammalian copper transporter 1 in the cellular accumulation of cisplatin.

Authors:  Christopher A Larson; Preston L Adams; Danielle D Jandial; Brian G Blair; Roohangiz Safaei; Stephen B Howell
Journal:  Biochem Pharmacol       Date:  2010-05-06       Impact factor: 5.858

Review 2.  The pervasiveness of macropinocytosis in oncological malignancies.

Authors:  Cosimo Commisso
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-02-04       Impact factor: 6.237

Review 3.  New roles for copper metabolism in cell proliferation, signaling, and disease.

Authors:  Michelle L Turski; Dennis J Thiele
Journal:  J Biol Chem       Date:  2008-08-29       Impact factor: 5.157

Review 4.  Overcoming platinum drug resistance with copper-lowering agents.

Authors:  Helen H W Chen; Macus Tien Kuo
Journal:  Anticancer Res       Date:  2013-10       Impact factor: 2.480

5.  Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases.

Authors:  Xiying Shang; Xinjian Lin; Edwin Alvarez; Gerald Manorek; Stephen B Howell
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

6.  Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1.

Authors:  Danielle D Jandial; Salman Farshchi-Heydari; Christopher A Larson; Gregory I Elliott; Wolfgang J Wrasidlo; Stephen B Howell
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

7.  The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs.

Authors:  Christopher A Larson; Brian G Blair; Roohangiz Safaei; Stephen B Howell
Journal:  Mol Pharmacol       Date:  2008-11-07       Impact factor: 4.436

8.  Differential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissue.

Authors:  Virginia Ip; Johnson J Liu; Julian F B Mercer; Mark J McKeage
Journal:  Mol Pain       Date:  2010-09-13       Impact factor: 3.395

9.  Molecular modulation of the copper and cisplatin transport function of CTR1 and its interaction with IRS-4.

Authors:  Cheng-Yu Tsai; Christopher A Larson; Roohangiz Safaei; Stephen B Howell
Journal:  Biochem Pharmacol       Date:  2014-06-23       Impact factor: 5.858

10.  Circumventing tumor resistance to chemotherapy by nanotechnology.

Authors:  Xing-Jie Liang; Chunying Chen; Yuliang Zhao; Paul C Wang
Journal:  Methods Mol Biol       Date:  2010
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.